

4 September 2020

Dear Healthcare Professional,

Supply of Australian-labelled Setrona 50 mg and 100 mg tablets in New Zealand

Douglas Pharmaceuticals is temporarily supplying Setrona (sertraline hydrochloride) 50 mg and 100mg tablets in Australian packaging to the New Zealand market, to cover a medicine shortage due to unprecedented demand.

Please note the formulation, method of manufacture, packaging material, storage condition and shelf life are identical between the New Zealand and Australian products.

The Australian pack includes a Consumer Medicines Information leaflet as a package insert, which is not provided in the New Zealand pack. The Consumer Medicines Information leaflet reflects the information within the New Zealand Data Sheet for Setrona. The prescribing and provision of patient counselling by healthcare professionals should continue in accordance with the New Zealand Data Sheet for Setrona that may be accessed at www.medsafe.govt.nz.

New Zealand Setrona	Australian Setrona



+64 9 835 0660



Douglas Pharmaceuticals Ltd
Central Park Drive, Lincoln
PO Box 45 027, Auckland 0651



www.douglas.co.nz



Reporting Adverse Events

Reporting suspected adverse reactions has an important role in monitoring the benefit/risk balance of medicines. Please report any suspected adverse events via email to Douglas Pharmaceuticals Ltd at drugsafety@douglas.co.nz. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) at <https://nzphvc.otago.ac.nz/>. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset and treatment dates.

If you have any questions related to this product, please contact Douglas Customer Services on 0800 368 452.

Kind regards,

Carl Petersen

Regional Manager ANZ Pharma